Solta Medical, Inc., together with its subsidiaries, designs, develops, manufactures, and markets energy-based medical device systems for aesthetic applications primarily in North America, the Asia Pacific, Europe, and the Middle East. It offers Fraxel re:pair system for use in dermatological procedures requiring ablation, coagulation, and resurfacing of soft tissue, as well as for rhytides, pigmentation, dyschromia, fine lines, acne, surgical scars, deeper lines, wrinkles, and actinic keratoses; and Clear + Brilliant system, a treatment to improve skin texture and help prevent the signs of aging skin. The company also provides Thermage CPT system that provides non-invasive treatment options...
25881 Industrial Boulevard
Hayward, CA 94545
Founded in 1996
Solta Medical, Inc. Launches Clear + Brilliant Pelo Laser
Sep 10 15
Solta Medical, Inc. announced the availability of the Clear + Brilliant pelo laser in the United States, a sophisticated approach to permanent hair reduction. The launch of this device, which joins the comprehensive portfolio of Solta Medical's aesthetic device solutions, follows a unique partnership with German Medical Engineering. The Clear + Brilliant pelo laser system uses a novel linear scanning approach with integrated contact cooling to deliver the effectiveness of current best-in-class diode laser hair removal technology with the fast and large treatment area available (50 mm by 15 mm). In addition, a unique all-inclusive subscription model will provide ease-of-mind and simplicity in ensuring consistent device performance and dependable support. Clear + Brilliant pelo will first be made exclusively available to current Solta Medical customers in the U.S, with full release scheduled in the fourth quarter of 2015.
Solta Medical, Inc. Announces Amendment and Restatement of Certificate of Incorporation
Jan 24 14
Solta Medical, Inc. amended and restated Certificate of Incorporation was amended and restated and the company's Amended and Restated Bylaws were amended and restated.
Solta Medical, Inc. Announces Management Changes
Jan 24 14
Pursuant to the terms of the Merger Agreement, on December 15, 2013, Solta Medical, Inc. entered into an Agreement and plan of merger with Valeant Pharmaceuticals International, Sapphire Subsidiary Corp. (the “Purchaser”), at the Effective Time, the directors and officers of the Purchaser immediately prior to the Effective Time became the directors and officers of Solta following the Effective Time. Accordingly, at the Effective Time, each of Mark M. Sieczkarek, Cathy L. McCarthy, David Holthe, Eric B. Stang, Harold Covert and Linda Graebner resigned as directors of Solta and any committee thereof. Each director resigned in accordance with the Merger Agreement, and no director resigned because of any disagreement with the Company on any matter relating to Solta’s operation, policies, or practices. Also at the Effective Time, Mr. Mark M. Sieczkarek, the Interim President and Chief Executive Officer, Mr. Jack Glenn, the Chief Financial Officer, Mr. H. Daniel Ferrari, Vice President of Finance, Mr. Doug W. Heigel, Vice President of Operations, Mr. Jeff Nardoci, Vice President of Worldwide Marketing, General Manager Surgical Specialties, and Dr. Lisa Parr, Vice President, Regulatory Affairs and Clinical Affairs, ceased being executive officers of Solta. At the Effective Time, Mr. J. Michael Pearson assumed the role of director, President and Chief Executive Officer of Solta, Mr. Howard B. Schiller assumed the role of director and Treasurer of Solta and Mr. Robert Chai-Onn assumed the role of director and Secretary of Solta. At the time Messrs. Schiller, Chai-Onn and Pearson assumed the roles of directors, it had not yet been determined on which committees, if any, of the Board of Directors of Solta Messrs. Schiller, Chai-Onn and Pearson would serve.